Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. - Wikidata - awgldk - TriplyDB

Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme.

Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme.

http://www.wikidata.org/entity/Q36977005

about

Diabetic Retinopathy in Italy: Epidemiology Data and Telemedicine Screening Programs Toward Big Data Analytics: Review of Predictive Models in Management of Diabetes and Its Complications Atomic data: James Mackenzie Lecture 2015.Biomarkers in Diabetic Retinopathy Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme.Automated diabetic retinopathy imaging in Indian eyes: a pilot study Diabetic retinopathy - ocular complications of diabetes mellitus.Determining diabetic retinopathy screening interval based on time from no retinopathy to laser therapy.Extending the diabetic retinopathy screening interval beyond 1 year: systematic review.The use of statistical methodology to determine the accuracy of grading within a diabetic retinopathy screening programme.Individualised variable-interval risk-based screening for sight-threatening diabetic retinopathy: the Liverpool Risk Calculation Engine.Diabetic Eye Screening: Knowledge and Perspectives from Providers and Patients.Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland.Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes.Screening Intervals for Diabetic Retinopathy and Implications for Care.Why Do Health Economists Promote Technology Adoption Rather Than the Search for Efficiency? A Proposal for a Change in Our Approach to Economic Evaluation in Health Care.Risk stratification for diabetic eye screening. Reply to Stratton I. M. and Aldington S. J. [letter].Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy.Fundus fluorescence Angiography in diagnosing diabetic retinopathy.Risk stratification for diabetic eye screening

P2860

Q28076765-5793DA55-8BE2-470D-8AE6-F93C7D34AD70 Q31005299-EBAEC026-3CF5-43FB-B954-DF0B57E0F6E4 Q31087371-1459519B-98C9-46BC-BA50-C6DBDA7D79BD Q33583030-142CFAC3-7EB9-48A8-931D-E564525AB0E4 Q33659440-0AD1830D-F9CF-4164-B232-CDAA9FAB51D3 Q35036826-E7797E80-36CF-4E72-8736-6B23F4F30778 Q35437840-FABE91FF-5BCC-4F38-B911-94A9861876ED Q36181803-7B219104-1941-4914-92D5-6B92C8424253 Q36475523-4CFDE320-E051-433A-8BF7-57DC1CA600A7 Q37248616-03D28532-0887-4689-A2D2-562771E7EF70 Q38608819-F346FE55-A039-4251-9EEE-07B6B4F17103 Q38635273-1E61DBDE-F95B-4786-B3A6-2690D123BC71 Q39867113-3E8F849B-A16F-4109-944C-5E96A5F3BFFC Q40236321-D6F305CE-1D5A-49E4-B570-F7F479207EBA Q40502875-43892591-84DC-4C11-842C-AB704BA3B0CC Q40694127-583D3837-17C6-474D-BC56-015B5BAF7D68 Q45923236-291AAF28-7626-4E95-BE88-C8651C683D3A Q46488287-39126058-A2D9-4026-93D6-EA869F1A8D33 Q50325304-AE67723A-E96F-45E4-A2AC-E2A77CF6D462 Q58678218-82CF420F-82CF-417D-A816-D544C4ED2F96

P2860

Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme.

http://www.wikidata.org/entity/Q36977005

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Predicted impact of extending ...... tinopathy Screening programme.

@en

type

label

Predicted impact of extending ...... tinopathy Screening programme.

@en

prefLabel

Predicted impact of extending ...... tinopathy Screening programme.

@en

P1433

Q36977005-A4A46F29-E8A9-4B22-904D-D90CD9584B68

P1476

Q36977005-1631B001-AA86-48E1-AC1D-7BA1A55AD5A7

P2093

Q36977005-047BF638-FB07-48B9-8517-A84EE9EDF011

Q36977005-13B0D5D0-9C29-485A-AF4B-EF0E371219E8

Q36977005-1B1B43B2-2589-4662-849D-EA633231A777

Q36977005-1F02427B-AB7F-4129-B10F-81AB3CC84BBB

Q36977005-2E84FC09-0AF2-4CD6-AA11-516FBB96D753

Q36977005-3859EFA7-B482-4F25-97B3-6E2979BEE666

Q36977005-4D535D92-760A-4697-BBA0-FA1E6C8FDF01

Q36977005-65FE609E-4234-410C-A9E0-AB662AAC19D7

Q36977005-6CF2F742-7F21-451A-ADE2-B207D083CDF8

Q36977005-7124A0BA-82E5-4390-8182-8C137FABC2EF

P2860

Q36977005-2249B29A-1BE7-4C7D-A67C-459428162BCA

Q36977005-2C0A5DDD-B6D8-4EA4-A52E-FA0C0675F627

Q36977005-501DC23A-6E46-45F9-9A01-0C87D9BADBBD

Q36977005-5C00601F-B1DB-44FA-882F-AE1DD424D44B

Q36977005-6E03C8E0-E19E-47C6-87F0-72BD7637D976

Q36977005-7FDE21B9-5730-401E-9235-8214FCCC344D

Q36977005-8C47C462-13DC-420D-903F-A7EAB766C170

Q36977005-95D46268-C07F-422A-B4FF-A6B3911EDC97

Q36977005-A66044E6-E645-4995-897E-CE9B867F8774

Q36977005-D0894B27-945D-41F9-9276-36B6CD879F56

P2888

Q36977005-1D755ADD-0297-46A3-A376-1C5893B5EA11

P304

Q36977005-26A59FDA-DED1-4F62-A78F-71C40325801E

P31

Q36977005-FD8890BA-E1FD-47DE-ACE0-C63F5241CE6F

P356

Q36977005-BBE0D803-63B4-41DB-8F3D-53C75880636E

P433

Q36977005-95B7A46F-0603-46C2-B79C-FE1BC0A3F959

P478

Q36977005-9D601B48-6FE0-4AC5-BF0B-0269B18AC71C

P50

Q36977005-72F9DCEF-177E-48F1-9D35-47EE1D5E94E2

P577

Q36977005-7B9424D8-C9AC-4ECC-BBFB-CD65366B7581

P5875

Q36977005-12D069FA-1026-4ADF-AE95-EEA06B1CD656

P698

Q36977005-2EAA7CAD-EDE1-4F15-8E93-126BD2396F90

P932

Q36977005-0A3D100B-566E-4DED-B368-EE860E6FBCCA

P356

S00125-013-2928-7

P1433

P1476

Predicted impact of extending ...... tinopathy Screening programme.

@en

P2093

A Briggs

http://www.w3.org/2001/XMLSchema#string

A D Morris

http://www.w3.org/2001/XMLSchema#string

D T Cromie

http://www.w3.org/2001/XMLSchema#string

D W M Pearson

http://www.w3.org/2001/XMLSchema#string

E J Hothersall

http://www.w3.org/2001/XMLSchema#string

G P Leese

http://www.w3.org/2001/XMLSchema#string

H C Looker

http://www.w3.org/2001/XMLSchema#string

H M Colhoun

http://www.w3.org/2001/XMLSchema#string

J A McKnight

http://www.w3.org/2001/XMLSchema#string

J A Olson

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy.

Can the retinal screening interval be safely increased to 2 years for type 2 diabetic patients without retinopathy?

Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study.

The impact of the Health Technology Board for Scotland's grading model on referrals to ophthalmology services.

Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis.

Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England

Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland.

Biennial eye screening in patients with diabetes without retinopathy: 10-year experience

P2888

s00125-013-2928-7

P304

1716-1725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00125-013-2928-7

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257331115

http://www.w3.org/2001/XMLSchema#string

P698

23689796

http://www.w3.org/2001/XMLSchema#string

P932

3699707

http://www.w3.org/2001/XMLSchema#string